TERTIARY STRUCTURE DATA |
Equus caballus
|
theoretical model |
0.00 Å |
1L9I |
1L9I |
1L9I |
1L9I |
1L9I |
1L9I |
|
Homo sapiens
|
complex with N-[[2-methyl-4-hydroxycarbamoyl]but-4-yl-N]-benzyl-P-[phenyl]-P-[methyl]phosphinamide |
2.30 Å |
1B3D |
1B3D |
1B3D |
1B3D |
1B3D |
1B3D |
Chen et al., 1999 |
catalytic domain; complex with diphenylpiperidine sulfonamide inhibitor |
2.00 Å |
1B8Y |
1B8Y |
1B8Y |
1B8Y |
1B8Y |
1B8Y |
Pavlovsky et al., 1999 |
complex with N1-hydroxy-2-(3-hydroxy-propyl)-3-isobutyl-N4-[1-(2-methoxy-ethyl)-2-oxo-azepan-3-yl]-succinamide |
2.50 Å |
1BIW |
1BIW |
1BIW |
1BIW |
1BIW |
1BIW |
Natchus et al., 1998 |
NMR structure; complex with N-HYDROXY-2(R)- [4-METHOXYSULFONYL](3-PICOLYL)AMINO]-3-methylbutaneamide hydrochloride monohydrate inhibitor |
0.00 Å |
1BM6 |
1BM6 |
1BM6 |
1BM6 |
1BM6 |
1BM6 |
Li et al., 1998 |
complex with interstitial collagenase and PG-117025 inhibitor |
2.30 Å |
1BQO |
1BQO |
1BQO |
1BQO |
1BQO |
1BQO |
Pikul et al., 1998 |
catalytic domain; complex with RO-26-2812 synthetic inhibitor |
1.83 Å |
1C3I |
1C3I |
1C3I |
1C3I |
1C3I |
1C3I |
Steele et al., 2000 |
catalytic domain; complex with RO-26-2812 |
2.60 Å |
1C8T |
1C8T |
1C8T |
1C8T |
1C8T |
1C8T |
Steele et al., 2000 |
catalytic domain; complex with diphenyl piperidine sulfonamide |
1.80 Å |
1CAQ |
1CAQ |
1CAQ |
1CAQ |
1CAQ |
1CAQ |
Pavlovsky et al., 1999 |
catalytic domain; complex with 3-(1H-indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid inhibitor |
1.64 Å |
1CIZ |
1CIZ |
1CIZ |
1CIZ |
1CIZ |
1CIZ |
Pavlovsky et al., 1999 |
catalytic domain |
2.00 Å |
1CQR |
1CQR |
1CQR |
1CQR |
1CQR |
1CQR |
Chen et al., 1999 |
complex with N-hydroxy-4-[(4-methoxylphenyl)sulfonyl]-2,2-dimethyl-hexahydro-1,4-thiazepine-3(S)-carboxamide |
2.60 Å |
1D5J |
1D5J |
1D5J |
1D5J |
1D5J |
1D5J |
Almstead et al., 1999 |
complex with N-hydroxy 1N(4-methoxyphenyl)sulfonyl-4-(Z,E-N-methoxyimino)pyrrolidine-2R-carboxamide inhibitor |
2.00 Å |
1D7X |
1D7X |
1D7X |
1D7X |
1D7X |
1D7X |
Cheng et al., 1999 |
complex with N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl-piperazine-2-carboxamide inhibitor |
2.40 Å |
1D8F |
1D8F |
1D8F |
1D8F |
1D8F |
1D8F |
Cheng et al., 2000 |
catalytic domain; complex with 1-benzyl-3-(4-methoxy-benzenesulfonyl)-6-oxo-hexahydro-pyrimidine-4-carboxamide inhibitor |
2.44 Å |
1D8M |
1D8M |
1D8M |
1D8M |
1D8M |
1D8M |
Pikul et al., 2001 |
catalytic domain; complex with heterocycle-based inhibitor |
2.45 Å |
1G05 |
1G05 |
1G05 |
1G05 |
1G05 |
1G05 |
Pikul et al., 2001 |
catalytic domain; complex with carboxylic acid based inhibitor (1N)-4-N-butoxyphenylsulfonyl-(2R)-N-hydroxycarboxamido-(4S)-methanesulfonylamino-pyrrolidine |
1.90 Å |
1G49 |
1G49 |
1G49 |
1G49 |
1G49 |
1G49 |
Natchus et al., 2000 |
catalytic domain; complex with HQQ inhibitor |
2.00 Å |
1G4K |
1G4K |
1G4K |
1G4K |
1G4K |
1G4K |
Dunten et al., 2001 |
catalytic domain; complex with N-carboxy-alkyl inhibitor L-764,004 |
1.70 Å |
1HFS |
1HFS |
1HFS |
1HFS |
1HFS |
1HFS |
Esser et al., 1997 |
catalytic domain; complex with a carboxylic acid based inhibitor |
1.50 Å |
1HY7 |
1HY7 |
1HY7 |
1HY7 |
1HY7 |
1HY7 |
Natchus et al., 2001 |
theoretical model |
0.00 Å |
1M1W |
1M1W |
1M1W |
1M1W |
1M1W |
1M1W |
|
NMR structure; complex with human stromelysin catalytic domain |
0.00 Å |
1OO9 |
1OO9 |
1OO9 |
1OO9 |
1OO9 |
1OO9 |
Arumugam & Van, 2003 |
catalytic domain |
2.00 Å |
1QIA |
1QIA |
1QIA |
1QIA |
1QIA |
1QIA |
Pavlovsky et al., 1999 |
catalytic domain; complex with diphenylpiperidine inhibitor |
2.00 Å |
1QIC |
1QIC |
1QIC |
1QIC |
1QIC |
1QIC |
Pavlovsky et al., 1999 |
C-truncated proenzyme |
1.90 Å |
1SLM |
1SLM |
1SLM |
1SLM |
1SLM |
1SLM |
Becker et al., 1995 |
catalytic domain; complex with the N-carboxyl-alkyl inhibitor L-702,842 |
2.27 Å |
1SLN |
1SLN |
1SLN |
1SLN |
1SLN |
1SLN |
Becker et al., 1995 |
catalytic domain; complex with TIMP-1 |
2.80 Å |
1UEA |
1UEA |
1UEA |
1UEA |
1UEA |
1UEA |
Gomis-Ruth et al., 1997 |
NMR structure of catalytic domain; complex with (R,S)-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-Leu-Phe-NH2 inhibitor |
0.00 Å |
1UMS |
1UMS |
1UMS |
1UMS |
1UMS |
1UMS |
Van et al., 1995 |
NMR structure; catalytic domain; complex with hydrophobic inhibitor |
0.00 Å |
1UMT |
1UMT |
1UMT |
1UMT |
1UMT |
1UMT |
Van et al., 1995 |
catalytic domain; complex with thiadiazole inhibitor PNU-142372 |
1.80 Å |
1USN |
1USN |
1USN |
1USN |
1USN |
1USN |
Finzel et al., 1998 |
stromelysin-1 (mmp-3) complexed to a hydroxamic acid inhibitor |
2.02 Å |
2D1O |
2D1O |
2D1O |
2D1O |
2D1O |
2D1O |
Kohno et al., 2006 |
mature peptidase |
0.00 Å |
2JNP |
2JNP |
2JNP |
2JNP |
2JNP |
2JNP |
Alcaraz et al., 2007 |
mature peptidase |
0.00 Å |
2JT5 |
2JT5 |
2JT5 |
2JT5 |
2JT5 |
2JT5 |
Alcaraz et al., 2007 |
mature peptidase |
0.00 Å |
2JT6 |
2JT6 |
2JT6 |
2JT6 |
2JT6 |
2JT6 |
Alcaraz et al., 2007 |
NMR structure of catalytic domain; complex with N-(R-carboxy-ethyl)-alpha-(S)-(2-phenyl ether) Gly-L-Arg-N-phenylamide |
0.00 Å |
2SRT |
2SRT |
2SRT |
2SRT |
2SRT |
2SRT |
Gooley et al., 1994 |
catalytic domain; complex with thiadiazole inhibitor PNU-141803 |
2.20 Å |
2USN |
2USN |
2USN |
2USN |
2USN |
2USN |
Finzel et al., 1998 |
mature peptidase |
2.36 Å |
3OHL |
3OHL |
3OHL |
3OHL |
3OHL |
3OHL |
|
mature peptidase |
2.50 Å |
3OHO |
3OHO |
3OHO |
3OHO |
3OHO |
3OHO |
|
NMR structure of catalytic domain; complex with thiadiazole inhibitor IPNU-107859 |
0.00 Å |
3USN |
3USN |
3USN |
3USN |
3USN |
3USN |
Stockman et al., 1998 |
mature peptidase |
1.96 Å |
4DPE |
4DPE |
4DPE |
4DPE |
4DPE |
4DPE |
Belviso et al., 2013 |
mature peptidase |
1.88 Å |
4G9L |
4G9L |
4G9L |
4G9L |
4G9L |
4G9L |
Belviso et al., 2013 |
mature peptidase |
1.96 Å |
4JA1 |
4JA1 |
4JA1 |
4JA1 |
4JA1 |
4JA1 |
Belviso et al., 2013 |
catalytic domain; complex with tissue inhibitor of metalloproteinase-1 (timp-1) mutant Leu34Gly |
2.37 Å |
6MAV |
6MAV |
6MAV |
6MAV |
6MAV |
6MAV |
|
catalytic domain; complex with tissue inhibitor of metalloproteinases-1 (timp-1) mutant (Leu34Gly/Leu133Pro/Leu151Cys/Gly154Ala) |
2.67 Å |
6N9D |
6N9D |
6N9D |
6N9D |
6N9D |
6N9D |
|